Skip to content

Physical Activity Modifies Exercise Responsiveness

Physical Activity Modifies Exercise Responsiveness: Implications for Rehabilitation in Veterans

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07792967
Enrollment
120
Registered
2026-08-28
Start date
2027-01-01
Completion date
2031-12-31
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multimorbidity

Brief summary

Exercise is the cornerstone of rehabilitation and an essential part of treatment plans for many chronic conditions; however, our understanding of why certain individuals respond positively to exercise while others do not remains incomplete. Physical inactivity and sedentary behavior have reached epidemic levels, coinciding with alarmingly high levels of multimorbidity in Veterans that, the investigators believe, impair exercise responsiveness and rehabilitation efficacy by disrupting the regulation of redox homeostasis and redox signaling by the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2). This project will use complementary approaches including 1) the Sit Less, Interact, Move More (SLIMM) intervention, and 2) PB125 to target Nrf2 and break the cycle of sedentary behavior, redox stress, functional impairments, and worsening multimorbidity in older Veterans.

Detailed description

Significance to VA: Sedentary behavior has emerged as a major risk factor for chronic conditions that are highly prevalent among older Veterans, including obesity, diabetes, and cardiovascular disease Innovation and Impact: Exercise is the cornerstone of rehabilitation and is an essential part of treatment plans for these conditions; however, our understanding of why certain individuals respond positively to exercise while others do not remains unclear. Epidemiological findings indicate that adhering to established exercise guidelines does not lower multimorbidity rates or mortality risk in individuals who spend most of their non-exercising time sedentary. Indeed, the negative impact of sedentary behavior on health cannot be offset by exercise alone, highlighting the critical need to prioritize reducing sedentary time in the treatment of age-related diseases. Preliminary data support these epidemiological findings and provide novel evidence that physical inactivity minimizes the beneficial effects of exercise, limiting exercise adaptation and rehabilitation effectiveness. This is particularly concerning as physical inactivity and sedentary behavior continue to increase among older Veterans coinciding with alarming levels of multimorbidity (60-80% of older Veterans have multimorbidity). Although the factors linking physical inactivity and exercise response variability have yet to be identified, aging and multimorbidity are associated with disruptions in redox homeostasis and impaired Nrf2 (nuclear factor erythroid 2-related factor 2) signaling. Nrf2 is a crucial exercise-responsive transcription factor that regulates antioxidant defenses, mitochondrial health, autophagy, and cellular resilience - processes essential for maintaining cellular function during aging. Our central hypothesis is that improving redox homeostasis by decreasing sedentary time or through targeted Nrf2 activation will enhance exercise responsiveness and improve vascular and skeletal muscle function. Specific Aim 1: Determine the impact of the Sit Less, Interact, Move More (SLIMM) intervention on exercise responsiveness, vascular function, and skeletal muscle function in older Veterans with multimorbidity. Hypothesis: The investigators hypothesize that reducing sedentary behavior and increasing physical activity through SLIMM will restore redox balance and, thereby, improve exercise responsiveness and enhance vascular and skeletal muscle function. Specific Aim 2: Determine the impact of targeted Nrf2 activation with PB125 on exercise responsiveness, vascular function, and skeletal muscle function in older Veterans with multimorbidity. Hypothesis: The investigators hypothesize that targeted Nrf2 activation will serve as an effective redox-based therapy to enhance exercise responsiveness and promote vascular and skeletal muscle function. Methodology: The investigators will use a SMART (Sequential Multiple Assignment Randomized Trial) study design in which older Veterans with multimorbidity will first undergo our Sit Less, Interact, Move More (SLIMM) intervention to decrease sedentary behavior and increase physical activity. Veterans that are compliant with SLIMM will continue with SLIMM for a total of 24 weeks. Participants that are not compliant with SLIMM will transition to targeted Nrf2 therapy with PB125, a novel and naturally occurring Nrf2 activator, at week 12 and will continue PB125 for 12 weeks. Exercise responsiveness, vascular function, and skeletal muscle function will be examined before and after the SLIMM and PB125 interventions. Path to Translation/Implementation: This project will provide evidence that redox homeostasis is critical for initiating and coordinating cellular and molecular processes underlying exercise adaptation and improvements in vascular and skeletal muscle health. The impact of this project is high and timely given the alarming rates of multimorbidity among older Veterans and the current gap in effective strategies to enhance physical function and health in this vulnerable population.

Interventions

BEHAVIORALSLIMM - Sit less, interact, move more

To minimize sedentary behavior and increase physical activity the investigators will use our SLIMM intervention. The goal of SLIMM is to replace 1 hour/day of sedentary duration with casual walking time. This goal is \~10% of the average baseline sedentary duration of 10.8 hours/day. While SLIMM is not anchored to a fixed percentage or step count increase, it operationalizes this goal through behavioral coaching and activity monitoring focused on increasing stepping time throughout the day. The SLIMM target duration for decreasing sedentary duration by 1 hour/day is based upon potential impact on energy expenditures and mortality from our previous National Health and Nutrition Examination Survey (NHANES) publication on sedentary behavior in patients with multimorbidity.

DIETARY_SUPPLEMENTPB125

The novel naturally derived activator of Nrf2, PB125, contains extracts from three botanical sources including i) Rosmarinus officinalis, standardized to carnosol content of 6%, 68 milligrams (mg) of extract; ii) Withania somnifera (aka Ashwagandha), standardized to withaferin A content of 1%, 23 milligrams (mg) of extract; and iii) Sophora Japonica, standardized to luteolin content of 98%, 9 milligrams (mg) of extract. Each extract can increase the nuclear translocation of Nrf2 and when combined, these extracts act in synergy through multiple control points to amplify and prolong the activation of Nrf2.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Participants that are non-compliant with SLIMM during phase 1 will transition to either PB125 or placebo. This portion of the trial will be double-blinded and placebo controlled.

Intervention model description

The investigators will use a SMART (Sequential Multiple Assignment Randomized Trial) study design in which older Veterans with multimorbidity will first undergo our Sit Less, Interact, Move More (SLIMM) intervention to decrease sedentary behavior and increase physical activity. Veterans that are compliant with SLIMM will continue with SLIMM for a total of 24 weeks. Participants that are not compliant with SLIMM will transition to targeted Nrf2 therapy with PB125, a novel and naturally occurring Nrf2 activator, at week 12 and will continue PB125 for 12 weeks. Exercise responsiveness, vascular unction, and skeletal muscle function will be examined before and after the SLIMM and PB125 interventions.

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Physically inactive, ≤5,000 steps/day 2. Multimorbidity Weighted Index between 6 to 11 3. Ability to sign informed consent 4. Montreal cognitive assessment (MOCA) exam score ≥26 5. Free-living and ambulatory prior to admission

Exclusion criteria

1. Multimorbidity Weighted Index \< 6 or \> 11 2. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma 3. Currently on a weight-loss diet or body mass index (BMI) \> 35 kilograms per square meter (kg/m2) (a BMI of 35 kg/m2, which includes individuals that fall into to the Class I obesity category, has been selected to improve inclusion and generalizability to a greater percentage of the general population) 4. Human immunodeficiency virus (HIV) or hepatitis B or C 5. Recent anabolic or corticosteroids use (within 3 months) 6. Subjects with hemoglobin or hematocrit lower than accepted lab values 7. Alcohol abuse (\> 2 drinks per day) or drug abuse (inappropriate use of prescription medications or use of any illicit/illegal drugs for recreational use) 8. Unwilling to cease dietary supplements 4 weeks prior to initiation intervention

Design outcomes

Primary

MeasureTime frameDescription
Vascular functionpre and post 12 and 24 weeks of interventionMeasured by flow-mediated dilation. Percent dilation (% FMD) from baseline to peak vasodilation. Measured by Doppler Ultrasound.
Muscle Strengthpre and post 12 and 24 weeks of interventionIsokinetic knee extensor muscle strength.
Physical Activitypre and post 12 and 24 weeks of interventionSteps per day.
Sedentary Behaviorpre and post 12 and 24 weeks of interventionTime spent sedentary measured in hours/day.

Countries

United States

Contacts

CONTACTJoel D Trinity, PhD
Joel.Trinity@va.gov(801) 582-1565
CONTACTBreannan Pack, BS
breannan.pack@va.gov(801) 582-1565
PRINCIPAL_INVESTIGATORJoel Douglas Trinity, PhD

VA Salt Lake City Health Care System, Salt Lake City, UT

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026